Clinical trial
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
NCT04058366 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 5, 2019
- Completion date
- December 16, 2022
- Enrollment
- 251 (actual)
- Sites
- 84
Conditions
As the registry lists them; a condition with its own page is linked.